BETA: Please send your feedback!
Under Armour
UAA:NYS
Apparel/Footwear
$8.11bn
MID cap
$17.97
(-1.01%)
0.01%
since start of 2019
94.93
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 2
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2001
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Kevin A. Plank, MBA | Chairman & Chief Executive Officer | Male |
| Kip J. Fulks | Chief Product Officer | Male |
| Lance Allega, MBA | Vice President-Investor Relations | Male |
| Kerry D. Chandler | Chief Human Resources Officer | Female |
| Paul Fipps | Chief Information Officer & EVP-Global Operations | Male |
| John P. Stanton | Secretary, Senior Vice President & General Counsel | Male |
| David E. Bergman | Chief Financial & Accounting Officer | Male |
| Clay Dean | Chief Innovation Officer | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
Five Prime Therapeutics - Competitors and Related Companies
How Five Prime Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Five Prime Therapeutics
FPRX:NAS
Biotechnology
$203.95mm
SMALL cap
$5.54
(-0.20%)
-0.42%
since start of 2019
-1.23
Loading…